Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2026
Trintellix promotional-payment allegations
The U.S. Department of Justice announced a $13,670,921 civil settlement with Takeda Pharmaceuticals U.S.A. concerning allegations that speaker honoraria and meals were provided to healthcare professionals to induce Trintellix prescriptions. The government stated that the claims resolved by the settlement were allegations and that there had been no determination of liability.
2014
Shire U.S. marketing-practices settlement
Before its acquisition by Takeda, Shire agreed to pay $56.5 million to resolve a U.S. government investigation concerning historical sales and marketing practices involving Adderall XR, Vyvanse, Daytrana, Lialda, and Pentasa. Shire also agreed to a separate Louisiana-related payment and a corporate integrity agreement. The matter is relevant to Takeda’s U.S. history because the affected businesses and products became part of Takeda in 2019.